De novo tuberculosis during infliximab therapy in a patient with Behçet disease.
A woman with oculocutaneous Behçet disease developed primary tuberculosis while being treated with infliximab. A latent tuberculosis infection had been excluded before therapy. After more than 80 weeks of treatment, the patient complained of fevers, night sweats, shivering and vigorous cough. The chest x-ray showed miliary shadowing. Mycobacterium tuberculosis was identified. The history revealed recent contact to an individual with smear-positive tuberculosis. This constellation speaks in favor of a de novo tuberculosis infection with a fulminant course.
Skvara
Hans
H
Department of Dermatology, Division of Immunodermatology and Infectious Skin Diseases, Medical University of Vienna, Austria. hans.skvara@meduniwien.ac.at
Duschek
Nikolaus
N
Karlhofer
Franz
F
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D014382:Tuberculosis, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab